3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Active not recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Conditions
Prostatic Neoplasms
7
Recurrence
2
Neoplasms
2
Prostate Cancer, Hereditary, 7
1
Metastatic Castration-resistant Prostate Cancer
1
Carcinoma
1
Adenocarcinoma
1
Interventions
Cisplatin
10
pembrolizumab
8
Carboplatin
8
Paclitaxel
6
durvalumab
5
Pemetrexed
5
1-(1-(imidazo(1,2-a)pyridin-6-yl)ethyl)-6-(1-methyl-1H-pyrazol-4-yl)-1H-(1,2,3)triazolo(4,5-b)pyrazine
5
osimertinib
4
Specimen Handling
4
Magnetic Resonance Spectroscopy
4
Taxes
3
Nivolumab
3
Gemcitabine
3
Docetaxel
3
Bevacizumab
3
cabozantinib
2
atezolizumab
2
Sunitinib
2
Radiotherapy, Intensity-Modulated
2
Radiotherapy
2
Radiation
2
Platinum
2
Immunoglobulin G
2
Disulfides
2
CP protocol
2
Biopsy
2
1,2-diaminocyclohexaneplatinum II citrate
2
trifluridine tipiracil drug combination
1
tremelimumab
1
relatlimab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Active not recruiting
×
Carcinoma
×
cabazitaxel
×
Clear all
NCT02202772
2025-02-24
CGC
Columbia University
Phase 1/2
Active not recruiting
51 enrolled